Miyarisan Pharmaceutical

What Miyarisan Pharmaceutical does

Miyarisan Pharmaceutical Co., Ltd. is a Tokyo-headquartered, privately-held specialty pharmaceutical company founded in 1947 and operating exclusively around a single biological platform: the spore-forming anaerobic bacterium Clostridium butyricum MIYAIRI (CBM/C. butyricum Miyairi), discovered in 1933 by Dr. Chōji Miyairi at Chiba Medical School. The company manufactures and sells prescription pharmaceuticals (notably the MiyaBM Tablets and MiyaBM Fine Granules probiotic intestinal regulators), OTC drugs and quasi-drugs, animal-health products (veterinary drugs, feed additives, mixed feeds), and pet health supplements. Its core technology — CBM as an acid- and antibiotic-resistant spore that survives gastric transit and produces butyric acid in the large intestine — underpins every franchise and supports secondary claims including antibiotic-resistance gene transfer suppression. Manufacturing is concentrated at two plants in Sakaki-machi, Nagano, including a FAMI-QS-certified facility dedicated to feed additives, with R&D housed in the Saitama Central Research Institute and an Innovation Center.

The company operates a multi-channel go-to-market model: a Japanese Medical Representative (MR) sales force covering hospitals, clinics, and pharmacies for prescription pharmaceuticals; an animal-health field-sales team serving veterinarians and livestock farmers; route sales to major drugstore chains for OTC and quasi-drug products; and international distribution through Huvepharma (EU/UK), BASF co-marketing (Miya-Phos E feed additive and BalanGut LS P), and Ardol (Lianol mixed feed imports from the Netherlands). The CBM strain is the first live microorganism ever to receive Novel Food approval from the European Commission, enabling commercial sales across all 27 EU member states and the UK, with Italy as the initial launch market. International operations also extend through the El Segundo, California-based subsidiary Miyarisan Pharmaceutical America, Inc., covering North America.

Miyarisan has no external funding history, is not publicly listed, and does not disclose revenue or headcount. Recent disclosures — particularly the January 2026 limited-shipment announcement citing 'unprecedented surge in demand exceeding production capacity' for the MiyaBM franchise — indicate meaningful organic demand growth that has outpaced internal production planning. Ongoing pipeline R&D targets Live Biotherapeutic Products (LBPs) for inflammatory bowel disease, colorectal cancer, autoimmune disorders, obesity, and autism. The company is structurally a single-strain, vertically-integrated specialty probiotic manufacturer leveraging legacy IP, regulatory exclusivity, and a domestic Japanese field-sales infrastructure into adjacent human, animal, and international markets.

Name

Miyarisan Pharmaceutical

Legal name

ミヤリサン製薬株式会社 (Miyarisan Pharmaceutical Co., Ltd.)

Website

https://miyarisan.com

Company type

Private

Founded year

1947

Operating status

Operating

Headcount range

1–10 employees

Short description

Miyarisan Pharmaceutical is a Tokyo-based, privately-held specialty pharma company that develops, manufactures, and sells probiotic pharmaceuticals, OTC drugs, animal-health feed additives, and pet supplements based on its proprietary Clostridium butyricum MIYAIRI spore-forming anaerobic bacterium, serving hospitals, veterinarians, livestock farmers, and consumers in Japan and internationally.

Ownership category

akta.pro rank

Product category

Probiotic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Microbiome-Derived Metabolite Therapeutics (postbiotics) (HLAAAFAB)

akta.pro secondary industries

Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials) (AFADALAE), Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI) (HLAMAHAH), Probiotics (Human & Animal Strains, Spore-Formers, Synbiotic Bases) (AFAJAJAE), Antimicrobials & Anti-infectives (HLAMAEAE)

Keywords

• Probiotic pharmaceuticals
• Live biotherapeutic products
• Intestinal regulator drugs
• Veterinary feed additives
• Gut microbiome therapeutics

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices15 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Prescription Pharmaceuticals: Prescription pharmaceutical products (医療用医薬品) including Miya BM tablets and powder for intestinal regulation, sold to hospitals and pharmacies through medical representatives.
2. OTC and Consumer Health Products: General pharmaceuticals (一般用医薬品), quasi-drugs (医薬部外品), and health supplements sold through major drugstore chains and pharmacies.
3. Animal Health Products: Veterinary pharmaceuticals, feed additives, and mixed feeds for livestock health, distributed to veterinarians and livestock farmers.
4. Pet Health Supplements: Pet health supplements (犬猫用健康補助食品) for dogs and cats sold to pet owners.
5. International Export and Licensing: Export of proprietary Clostridium butyricum MIYAIRI products to international markets including East Asia, Southeast Asia, EU, UK, and USA. Received EU Novel Food approval as first live microorganism to achieve this designation.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Miyarisan Pharmaceutical researches, manufactures, and sells pharmaceutical products built around its proprietary Clostridium butyricum MIYAIRI (CBM) spore-forming bacteria strain, discovered in 1933. Its offering spans prescription probiotic intestinal regulators (MiyaBM Tablets and Fine Granules), antiemetic films, dermatology topicals, OTC drugs and quasi-drugs for consumer health, veterinary pharmaceuticals and probiotic feed additives, and pet health supplements for dogs and cats.

Product overview

Miyarisan Pharmaceutical is a probiotic-focused pharmaceutical company founded in 1947, built around its proprietary Clostridium butyricum MIYAIRI (CBM) strain discovered in 1933. The company operates across three main product domains: (1) Prescription pharmaceuticals led by the MiyaBM franchise (MiyaBM Tablets and MiyaBM Fine Granules) as core probiotic intestinal regulators, supplemented by the antiemetic Ondansetron OD Film and dermatology products (DERMACRIN A Ointment, DERMACRIN Cream, HIDEMAART Cream); (2) Over-the-counter drugs and quasi-drugs for general consumer health; and (3) Animal health products including feed additives, veterinary drugs, and pet supplements. The company also develops novel Live Biotherapeutic Products (LBPs) targeting specific diseases. The product portfolio is characterized by the central role of the CBM strain across human and animal health applications under the One Health concept.

Differentiator

Problem solved

Functional benefit

Products and services

• MiyaBM Tablets (ミヤBM錠)

Quantifiable outcome

• Clostridium butyricum MIYAIRI is the first live microorganism to receive Novel Food approval from the European Commission, enabling marketing in all EU and UK markets

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• BASFcoreStrategic or Co-development Partner · 1 January 2020Joint development and domestic partnership with BASF (Germany), one of the world's leading chemical producers. Jointly developed products include 'Miya-Phos E' feed additive combining BASF's phytase Natuphos E with company's CBM. Also distributes BASF's 'BalanGut LS P' product through domestic partnership since 2022. Partnership aims for further business development in animal nutrition.
• HuvepharmacoreChannel Partner/ Reseller/ DistributorHuvepharma (headquartered in Bulgaria) imports and distributes CBM G Powder, the raw material for probiotic feed additive 'Miya-Gold EU', enabling Miyarisan's feed additive business in European markets. This partnership supports exports to all 27 EU countries and the UK.
• Ardol (Netherlands)minorChannel Partner/ Reseller/ DistributorImport partnership for Lianol mixed feed product line from Ardol in the Netherlands, complementing Miyarisan's animal health portfolio in the Japanese market.
• Academic and Research InstitutionscoreStrategic or Co-development PartnerActive industry-academia collaboration (産学共同研究) with universities, medical schools, and public research institutions in Japan and internationally. Multi-omics research (genomics, proteomics) on microbiome and anaerobic bacteria for novel drug discovery.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Yakult Honsha: Japan's leading probiotic pharmaceutical/consumer health company, maker of the Lactobacillus casei strain Shirota-based Yakult drink. Directly comparable as a Japanese probiotic-focused company with pharmaceutical-grade research heritage, multiple product forms, and global distribution of live bacterial products.
• Morinaga Milk Industry: Japanese dairy and probiotics company with Bifidobacterium-based pharmaceutical and consumer health products, including prescription probiotic formulations. Comparable as a Japan-based probiotics specialist with both human pharma and food/supplement channels.
• BioGaia: Swedish probiotics specialist focused on Lactobacillus reuteri strains for human and animal health, with pharmaceutical-grade research and a similar business model spanning prescription, OTC, and animal health segments. Most direct global comparator for a single-strain probiotic pharmaceutical company.

Broad incumbents

• ADM Animal Nutrition: Global animal nutrition major with a broad portfolio of feed additives including probiotics and antibiotic alternatives. Comparable to Miyarisan's animal health feed additive business, particularly in the EU where Miya-Gold EU competes with ADM's microbiome product lines.
• Huvepharma: Bulgarian-headquartered global animal health and nutrition company, and Miyarisan's distribution partner for Miya-Gold EU. Comparable as a major feed additive and animal health player with overlapping probiotic and antibiotic-alternative product portfolios.
• Meiji Holdings: Japanese conglomerate with a major pharmaceutical division (Meiji Seika Pharma) producing gastrointestinal, dermatology, and animal health products. Comparable for the prescription pharma, OTC consumer health, and animal health portfolio overlap.
• Novonesis (formerly Chr. Hansen): Global leader in microbial and fermentation-based products including probiotic cultures for human and animal health. A broader incumbent with a much larger portfolio of bacterial strains and a well-established global B2B ingredient supply business to which Miyarisan's CBM business is comparable.
• Ferring Pharmaceuticals: Swiss specialty pharmaceutical company with a leading gastroenterology franchise and active microbiome therapeutics R&D. Comparable for prescription probiotic/biotherapeutic products targeting intestinal disorders and the strategic direction of Miyarisan's LBP pipeline.

Emerging players

• Adare Pharmaceuticals (now Adare Biome): Specialty pharmaceutical and microbiome company developing Live Biotherapeutic Products for gastrointestinal and inflammatory conditions. Comparable as an emerging player pursuing the same LBP development path that Miyarisan has signalled in its R&D pipeline.
• 4D pharma: Clinical-stage biopharmaceutical company developing single-strain Live Biotherapeutic Products for cancer, gastrointestinal, and respiratory diseases. Highly comparable for Miyarisan's stated LBP ambitions in oncology and autoimmune disease, though much earlier stage and purely clinical.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Miyarisan Pharmaceutical